- Home
- REVB vs BDRX Comparison
REVB vs BDRX Comparison
Compare REVB & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- BDRX
- Stock Information
- Founded
- REVB 2020
- BDRX 2000
- Country
- REVB United States
- BDRX United Kingdom
- Employees
- REVB N/A
- BDRX N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- BDRX Health Care
- Exchange
- REVB Nasdaq
- BDRX Nasdaq
- Market Cap
- REVB 3.4M
- BDRX 3.9M
- IPO Year
- REVB N/A
- BDRX N/A
- Fundamental
- Price
- REVB $1.53
- BDRX $8.11
- Analyst Decision
- REVB
- BDRX
- Analyst Count
- REVB 0
- BDRX 0
- Target Price
- REVB N/A
- BDRX N/A
- AVG Volume (30 Days)
- REVB 994.9K
- BDRX 25.1K
- Earning Date
- REVB 11-07-2025
- BDRX 09-23-2025
- Dividend Yield
- REVB N/A
- BDRX N/A
- EPS Growth
- REVB N/A
- BDRX N/A
- EPS
- REVB N/A
- BDRX N/A
- Revenue
- REVB N/A
- BDRX N/A
- Revenue This Year
- REVB N/A
- BDRX N/A
- Revenue Next Year
- REVB N/A
- BDRX N/A
- P/E Ratio
- REVB N/A
- BDRX N/A
- Revenue Growth
- REVB N/A
- BDRX N/A
- 52 Week Low
- REVB $1.35
- BDRX $5.00
- 52 Week High
- REVB $60.48
- BDRX $108.90
- Technical
- Relative Strength Index (RSI)
- REVB 35.53
- BDRX 73.06
- Support Level
- REVB $1.40
- BDRX $6.33
- Resistance Level
- REVB $1.59
- BDRX $7.00
- Average True Range (ATR)
- REVB 0.09
- BDRX 0.44
- MACD
- REVB 0.03
- BDRX 0.10
- Stochastic Oscillator
- REVB 44.90
- BDRX 91.56
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.